JP6483442B2 - Ｐｄｇｆ受容体ベータ結合ポリペプチド - Google Patents

Ｐｄｇｆ受容体ベータ結合ポリペプチド Download PDF

Info

Publication number
JP6483442B2
JP6483442B2 JP2014546016A JP2014546016A JP6483442B2 JP 6483442 B2 JP6483442 B2 JP 6483442B2 JP 2014546016 A JP2014546016 A JP 2014546016A JP 2014546016 A JP2014546016 A JP 2014546016A JP 6483442 B2 JP6483442 B2 JP 6483442B2
Authority
JP
Japan
Prior art keywords
pdgfrβ
amino acid
binding
seq
binding polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014546016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501814A (ja
JP2015501814A5 (enExample
Inventor
チェン，ヤン
ワグナー，リチャード・ダブリュ
パズマニー，クサバ
Original Assignee
エックス−ボディ インコーポレイテッド
エックス−ボディ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス−ボディ インコーポレイテッド, エックス−ボディ インコーポレイテッド filed Critical エックス−ボディ インコーポレイテッド
Publication of JP2015501814A publication Critical patent/JP2015501814A/ja
Publication of JP2015501814A5 publication Critical patent/JP2015501814A5/ja
Application granted granted Critical
Publication of JP6483442B2 publication Critical patent/JP6483442B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014546016A 2011-12-05 2012-12-05 Ｐｄｇｆ受容体ベータ結合ポリペプチド Active JP6483442B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161566778P 2011-12-05 2011-12-05
US61/566,778 2011-12-05
US201261610905P 2012-03-14 2012-03-14
US61/610,905 2012-03-14
PCT/US2012/067909 WO2013085972A1 (en) 2011-12-05 2012-12-05 Pdgf receptor beta binding polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018216510A Division JP6843816B2 (ja) 2011-12-05 2018-11-19 Ｐｄｇｆ受容体ベータ結合ポリペプチド

Publications (3)

Publication Number Publication Date
JP2015501814A JP2015501814A (ja) 2015-01-19
JP2015501814A5 JP2015501814A5 (enExample) 2016-01-14
JP6483442B2 true JP6483442B2 (ja) 2019-03-13

Family

ID=48574820

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546016A Active JP6483442B2 (ja) 2011-12-05 2012-12-05 Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP2018216510A Expired - Fee Related JP6843816B2 (ja) 2011-12-05 2018-11-19 Ｐｄｇｆ受容体ベータ結合ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018216510A Expired - Fee Related JP6843816B2 (ja) 2011-12-05 2018-11-19 Ｐｄｇｆ受容体ベータ結合ポリペプチド

Country Status (9)

Country Link
US (4) US9416179B2 (enExample)
EP (2) EP3712173B1 (enExample)
JP (2) JP6483442B2 (enExample)
CN (2) CN107353342B (enExample)
AU (1) AU2012347972B2 (enExample)
CA (1) CA2857721C (enExample)
ES (1) ES2784131T3 (enExample)
TW (2) TWI591074B (enExample)
WO (1) WO2013085972A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094565A1 (en) 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP3798236B1 (en) 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
CN107353342B (zh) * 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽
HRP20230276T1 (hr) 2012-03-20 2023-04-28 Eagle Pharmaceuticals, Inc. Tekući pripravci bendamustina za uporabu u postupku liječenja stanja koja reagiraju na bendamustin kod pacijenata kojima za primjenu trebaju reducirani volumeni
ES2972227T3 (es) 2012-03-20 2024-06-11 Eagle Pharmaceuticals Inc Formulaciones de bendamustina
CN105026433B (zh) * 2014-01-24 2018-10-19 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
CA2943242A1 (en) * 2014-03-21 2015-09-24 X-Body, Inc. Bi-specific antigen-binding polypeptides
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Ｆｌｔ３に特異的な抗体およびその使用
US12098206B2 (en) 2018-10-05 2024-09-24 Seoul National University R&Db Foundation PDGF receptor antibody and use thereof
JP2020146298A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146310A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146300A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146312A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146297A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146307A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146317A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146318A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146303A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146301A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146314A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146309A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146302A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146306A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146308A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146304A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146305A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146315A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146299A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146311A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
JP2020146316A (ja) * 2019-03-14 2020-09-17 株式会社三洋物産 遊技機
BR112021026309A2 (pt) 2019-06-26 2022-06-07 Ap Biosciences Inc Anticorpos para ativação de células t
JP7774293B2 (ja) * 2019-07-24 2025-11-21 国立研究開発法人科学技術振興機構 抗体酵素の革新的製造技術
EP4110819A1 (en) * 2020-02-28 2023-01-04 Apexigen, Inc. Anti-sirpa antibodies and methods of use
CN119039440A (zh) * 2021-07-02 2024-11-29 来凯医药科技(上海)有限公司 活化的肝星状细胞（hsc）的消耗及其用途
CN114369163B (zh) * 2022-02-18 2024-02-23 中国科学技术大学 与人血小板衍生生长因子受体β结合的羊驼源纳米抗体
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
CN121378405B (zh) * 2025-11-28 2026-07-17 首都医科大学附属北京口腔医院 一种pdgfd衍生肽及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DE69233125T2 (de) 1991-12-02 2004-04-22 Millennium Pharmaceuticals, Inc., South San Francisco Inhibitorische immunglobulin-polypeptide gegen den pdgf beta-rezeptor
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU3968897A (en) 1996-08-02 1998-02-25 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
EP1068356B8 (en) 1998-04-03 2007-01-03 Adnexus Therapeutics, Inc. Addressable protein arrays
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
DK1105360T3 (da) 1998-08-17 2009-11-02 Bristol Myers Squibb Co Identifikation af forbindelse-protein-interaktioner ved anvendelse af biblioteker af protein-nukleinsyrefusionsmolekyler
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
CA2334946A1 (en) 1998-08-17 2000-02-24 Phylos, Inc. Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular rna-protein fusion formation
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6623926B1 (en) 1999-06-01 2003-09-23 Phylos, Inc. Methods for producing 5′-nucleic acid-protein conjugates
IL146451A0 (en) 1999-07-12 2002-07-25 Phylos Inc C-terminal protein tagging
CA2377468C (en) 1999-07-27 2010-04-20 Phylos, Inc. Peptide acceptor ligation methods
CA2382545C (en) 1999-08-27 2013-08-13 Phylos, Inc. Methods for encoding and sorting in vitro translated proteins
EP1250463B1 (en) 2000-01-24 2006-04-05 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
WO2002084277A1 (en) 2001-04-17 2002-10-24 Abmaxis, Inc. Structure-based construction of human antibody library
WO2003000856A2 (en) 2001-06-21 2003-01-03 Phylos, Inc. In vitro protein interaction detection systems
JP2005289809A (ja) * 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US7125669B2 (en) 2001-11-27 2006-10-24 Compound Therapeutics, Inc. Solid-phase immobilization of proteins and peptides
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
ATE480562T1 (de) 2002-10-15 2010-09-15 Facet Biotech Corp Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
GB0226729D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
JP4762156B2 (ja) 2004-01-12 2011-08-31 アプライド モレキュラー エボリューション，インコーポレイテッド Ｆｃ領域変異体
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
US20080206585A1 (en) * 2007-02-22 2008-08-28 Kennametal Inc. Composite materials comprising a hard ceramic phase and a Cu-Ni-Mn infiltration alloy
EA019595B1 (ru) * 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
US20110022149A1 (en) 2007-06-04 2011-01-27 Cox Brian J Methods and devices for treatment of vascular defects
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
EP3798236B1 (en) * 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CN107353342B (zh) * 2011-12-05 2021-08-10 X 博迪生物科学公司 PDGF受体β结合多肽

Also Published As

Publication number Publication date
AU2012347972B2 (en) 2018-05-10
EP2788379A4 (en) 2015-05-06
TW201333038A (zh) 2013-08-16
US9416179B2 (en) 2016-08-16
CN107353342A (zh) 2017-11-17
CN104105708A (zh) 2014-10-15
CN104105708B (zh) 2018-04-03
AU2012347972A1 (en) 2014-06-19
US20130177572A1 (en) 2013-07-11
CA2857721A1 (en) 2013-06-13
US20200299390A1 (en) 2020-09-24
TWI591074B (zh) 2017-07-11
US20220089748A1 (en) 2022-03-24
EP3712173B1 (en) 2023-07-12
US20170029510A1 (en) 2017-02-02
JP2015501814A (ja) 2015-01-19
US11136398B2 (en) 2021-10-05
EP2788379A1 (en) 2014-10-15
WO2013085972A1 (en) 2013-06-13
US10604578B2 (en) 2020-03-31
JP2019047807A (ja) 2019-03-28
CA2857721C (en) 2022-05-31
EP3712173A1 (en) 2020-09-23
ES2784131T3 (es) 2020-09-22
CN107353342B (zh) 2021-08-10
EP2788379B1 (en) 2020-02-05
TW201802117A (zh) 2018-01-16
JP6843816B2 (ja) 2021-03-17
TWI640537B (zh) 2018-11-11
HK1202882A1 (en) 2015-10-09

Similar Documents

Publication Publication Date Title
JP6843816B2 (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP7048567B2 (ja) 二重特異性抗原結合ポリペプチド
HK40037402A (en) Pdgf receptor beta binding polypeptides
HK40035879A (en) Bi-specific antigen-binding polypeptides
HK1202882B (en) Pdgf receptor beta binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181119

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20181211

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190214

R150 Certificate of patent or registration of utility model

Ref document number: 6483442

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250